Alpha-1 Antitrypsin Therapy Delays Arthritis in Mice
Author Information
Author(s): Christian Grimstein, Young-Kook Choi, Clive H Wasserfall, Minoru Satoh, Mark A Atkinson, Mark L Brantly, Martha Campbell-Thompson, Sihong Song
Primary Institution: University of Florida
Hypothesis
Can human alpha-1 antitrypsin (hAAT) therapy delay the development of arthritis in a mouse model?
Conclusion
Human AAT protein and gene therapies can delay arthritis development and reduce autoimmunity in a mouse model.
Supporting Evidence
- Human AAT therapy significantly delayed the onset of arthritis in treated mice.
- Serum levels of autoantibodies were reduced in mice receiving hAAT therapy.
- Both protein and gene therapies showed similar efficacy in delaying arthritis development.
Takeaway
This study shows that a protein called alpha-1 antitrypsin can help mice with arthritis feel better and get sick less often.
Methodology
Mice were treated with either hAAT protein or gene therapy and monitored for arthritis development and autoantibody levels.
Potential Biases
Potential bias in treatment administration and assessment of outcomes.
Limitations
The study was conducted in a mouse model, which may not fully replicate human conditions.
Participant Demographics
DBA/1 male mice, aged six weeks.
Statistical Information
P-Value
p = 0.029
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website